Astellas: Data show fidaxomicin's efficacy, cost savings
By BC Staff | Nov 27, 2014 | 1:56 AM GMT
Astellas Pharma Inc. (Tokyo:4503) said a pooled analysis showed that patients receiving fidaxomicin to treat Clostridium difficile infection (CDI) had reduced mortality, recurrence rates and healthcare costs
Read the full 278 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury